Arlette Arraut*, Mahwish Ahmed, Arshad Maqbool, Sumera Afzal, Kaniz F. Islam, Chet Bahadur Ranabhat, Anupa Shrestha, Anubhav Poudel, Moyosore Olatunde Olajuwon, Khin Myet Thwe, Rafay Shahab Ansari, Sohaib Tousif, Aimen Iqbal and Neni Diyanti


In Wuhan, China pneumonia of an unidentified source was reported in December, 2019. The World health organization (WHO) later termed this pneumonia as Corona Virus Infectious Disease 2019 (COVID-19) and declared this epidemic as pandemic after it hit most countries worldwide. There is an increase in the prevalence of diseases like cardiovascular disease (CVD), diabetes mellitus (DM), obesity and hypertension in critically ill COVID patients. Diabetes mellitus has been predicted as a significant risk aspect for mortality in covid-19 patients admitted to hospitals. However, the data about COVID-19 in patients with diabetes and associated comorbidities is inadequate yet. This review aims to figure out the clinical characteristics of severe COVID-19 patients with diabetes and evaluate the comorbidities and inferior outcomes of patients with COVID-19. The literature on COVID-19 related to diabetes mellitus (DM) and its worse effects was critically reviewed. A detailed literature search was carried out using a combination of different keywords; including of SARS-CoV-2/COVID19, diabetes and hyperglycemia/diabetes in various databases and nine studies were selected to exhibit the outcomes related to COVID-19 in diabetic patients. Older age and male sex are greatly related to the inferior effects in COVID-19 patients. As far as the population of minorities like ethnic minorities are concerned, the risk factors associated with cardiovascular problems like obesity, hypersensitivity and diabetes are responsible for severe outcomes. Furthermore, it was concluded that diabetes is a major risk factor for mortality in patients with severe COVID-19. Intensive care management should be applied to managing COVID-19 patients with diabetes mellitus (DM).

Keywords: .

[Full Text Article]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Tangudu Nagabhusana Rao

Download Article : Click here

News & Updation


    APRIL 2021 Issue has been successfully launched on 1 April 2021.

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction